| Feature Type | Standardized | Nominal ANOVA | ||||
|---|---|---|---|---|---|---|
| mRNA | MLN4924 | CTRPv2 | pan-cancer | AAC | -0.081 | 0.02 |
| mRNA | FQI-2 | CTRPv2 | pan-cancer | AAC | -0.076 | 0.02 |
| mRNA | BRD-K71935468 | CTRPv2 | pan-cancer | AAC | 0.09 | 0.02 |
| mRNA | Talazoparib | GDSC1000 | pan-cancer | AAC | -0.08 | 0.02 |
| mRNA | NPK76-II-72-1 | GDSC1000 | pan-cancer | AAC | -0.07 | 0.02 |
| mRNA | RDEA119 | FIMM | pan-cancer | AAC | 0.38 | 0.02 |
| mRNA | erlotinib:PLX-4032 (2:1 mol/mol) | CTRPv2 | pan-cancer | AAC | 0.086 | 0.02 |
| mRNA | Platin | CTRPv2 | pan-cancer | AAC | 0.085 | 0.02 |
| mRNA | rigosertib | CTRPv2 | pan-cancer | AAC | -0.074 | 0.02 |
| mRNA | TG-101348 | GDSC1000 | pan-cancer | AAC | -0.066 | 0.02 |